
|Videos|November 5, 2013
The Utility of Afatinib in Lung Cancer
Author(s)Tony S.K. Mok, BMSc, MD, FRCPC
Tony S.K. Mok, BMSc, MD, FRCPC, professor, Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital Hong Kong, China, discusses the utility of afatinib in patients with lung cancer.
Advertisement
Clinical Pearls
Tony S.K. Mok, BMSc, MD, FRCPC, professor, Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital Hong Kong, China, discusses the utility of afatinib in patients with lung cancer.
- Results from the LUX-Lung 3 trial demonstrated benefit with afatinib compared with cisplatin/pemetrexed in patients with advanced lung adenocarcinoma withEGFRmutations
- Afatinib is now available in the U.S.
- How afatinib compares with other TKIs is still up for debate
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
4
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
5







































